Tag: Myelofibrosis

Jan152025 by adminNo Comments

Diabetes Med for Kidney Stones? Workout and Heart Failure

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, take a look at the leading medical stories of the week. Today's subjects consist of catheter product for peripherally placed main catheter (PICC) lines, a diabetes medication for kidney stones, chauffeur anomaly clearance and regression forecast and workout and cardiac arrest. Program notes: 0:44 Exercise and cardiac arrest 1:44 322 clients with cardiac arrest and typical ejection portion 2:45 What portion continued? 3:30 Kidney stone avoidance with empagliflozin (Jardiance) 4:30 Once everyday followed by placebo 5:30 Also reliable in cardiac arrest 6:30...

Dec152023 by adminNo Comments

Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis

Health and Mediacal

Meeting Coverage > > ASH: Hematology-- Combos with navitoclax or pelabresib caused more clients accomplishing decreases by Mike Bassett, Staff Writer, MedPage Today December 12, 2023 SAN DIEGO-- Combining the Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) with either navitoclax or pelabresib resulted in more clients with myelofibrosis accomplishing decreases in spleen volume, 2 stage III research studies revealed. In the TRANSFORM-1 trial, the mix of the BCL-XL/BCL -2 inhibitor navitoclax and ruxolitinib doubled the variety of clients who accomplished a 35% or higher decrease in spleen volume (SVR35) by week 24 (63.2% vs 31.5%, P< 0.0001) compared to clients who...